The Precision Hypertension Care Study
NCT02774460 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 280
Last updated 2021-09-01
Summary
The PHYSIC study aims to investigate the potential for precision medicine in the treatment of high blood pressure.
It is a double-blind, randomized, repeated cross-over trial with six treatment periods: four classes of blood pressure-lowering drugs where treatment with two classes are repeated for each patient. The classes of blood pressure-lowering drugs to be tested are a diuretic, a calcium channel blocker, an ACE-inhibitor and an angiotensin receptor blocker.
Conditions
Interventions
- DRUG
-
Zestril®
Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
- DRUG
-
Atacand®
Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
- DRUG
-
Norvasc®
Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
- DRUG
-
Hydrochlorthiazide®
Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
- DRUG
-
Treatment X
Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
- DRUG
-
Treatment Y
Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
- DRUG
-
This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
Sponsors & Collaborators
-
Uppsala University
lead OTHER
Principal Investigators
-
Johan Sundstrom, Professor · Uppsala University, Department of Medical Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-02-20
- Primary Completion
- 2021-06-11
- Completion
- 2021-06-11
Countries
- Sweden
Study Locations
More Related Trials
-
Chronic Clinical Effect of Acetazolamide
NCT02755298 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension
NCT07294794 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study
NCT04190420 ·Status: ENROLLING_BY_INVITATION
-
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
NCT02603809 ·Status: COMPLETED ·Phase: PHASE2
-
Systolic Hypertension in Europe Placebo-Controlled Trial
NCT02088450 ·Status: TERMINATED ·Phase: PHASE2
-
Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.
NCT03640221 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluation of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension
NCT06515795 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure
NCT00925470 ·Status: COMPLETED
-
Hypertension Prevention Trial (HPT) Feasibility Study
NCT00000501 ·Status: COMPLETED ·Phase: PHASE2
-
Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
NCT05732727 ·Status: RECRUITING ·Phase: PHASE3
-
Antihypertensive Drug Selection Based on Hemodynamic Phenotypes
NCT07240909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Analysis of Antihypertensive Treatment Efficacy
NCT00767247 ·Status: TERMINATED
-
Feasibility Study of the Intensive Systolic Blood Pressure Control
NCT02817503 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effects of Potassium on Physiological and Cardiovascular Variables in Healthy Persons
NCT00801034 ·Status: COMPLETED ·Phase: PHASE1
-
Food Supplementation With Diuripres for Blood Pressure Modulation in Subjects With High-Normal Blood Pressure
NCT05167747 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
NCT06682000 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients
NCT02563405 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)
NCT03249285 ·Status: UNKNOWN ·Phase: PHASE3
-
New Biomarkers and Difficult-to-treat Hypertension
NCT03034265 ·Status: COMPLETED
-
Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension
NCT02755259 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Potassium Intake-response Trial to Control Hypertension
NCT05758142 ·Status: TERMINATED ·Phase: NA
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
NCT04971720 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Efficacy and Safety of AD-223
NCT06052748 ·Status: COMPLETED ·Phase: PHASE3
-
The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose
NCT00673790 ·Status: COMPLETED ·Phase: PHASE4
-
A Study in People With Mild Hypertension
NCT00374855 ·Status: COMPLETED ·Phase: PHASE2